ESR1 and breast cancer: Moreover, a distinct distribution across BC subtypes was observed: 18% were ER-negative/HER2-negative, 22% were HER2-positive, and 37% were ER-positive/HER2-negative, highlighting their potential role in this aggressive subtype [39].